Becton Dickinson and Company (BDX)vsDaxor Corporation (DXR)
BDX
Becton Dickinson and Company
$151.16
+1.07%
HEALTHCARE · Cap: $39.80B
DXR
Daxor Corporation
$10.60
-4.39%
HEALTHCARE · Cap: $61.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 83278278% more annual revenue ($22.23B vs $26,690). DXR leads profitability with a 34359.0% profit margin vs 5.1%. DXR trades at a lower P/E of 6.5x. BDX earns a higher WallStSmart Score of 65/100 (B-).
BDX
Strong Buy65
out of 100
Grade: B-
DXR
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+9.9%
Fair Value
$200.45
Current Price
$151.16
$49.29 discount
Intrinsic value data unavailable for DXR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 34359 of every $100 in revenue as profit
Earnings expanding 329.3% YoY
Conservative balance sheet, low leverage
Every $100 of equity generates 23 in profit
Areas to Watch
Moderate valuation
ROE of 4.7% — below average capital efficiency
5.1% margin — thin
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 82.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 34359.0% and operating margin at -9661.0%.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.
Bear Case : DXR
The primary concerns for DXR are Market Cap, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
BDX profiles as a value stock while DXR is a declining play — different risk/reward profiles.
BDX carries more volatility with a beta of 0.28 — expect wider price swings.
BDX is growing revenue faster at 5.2% — sustainability is the question.
BDX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (65/100 vs 45/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?